期刊文献+

肌细胞增强因子2在心力衰竭过程中的作用 被引量:1

The Effects of Myocyte Enhancer Factor 2 on the Process of Heart Failure
下载PDF
导出
摘要 心脏在长期过量负荷及神经体液系统过度激活的影响下,可发生以心肌细胞肥大、心肌纤维排列紊乱、心肌间质细胞增生及胚胎基因再表达增加为主的病理改变,从而引起心脏泵功能减退、心室扩张、心室肥厚和纤维化,最终导致心力衰竭。肌细胞增强因子2(myocyte enhancer factor 2,MEF2)是一种特定的转录因子,其主要功能是促进肌细胞分化过程中的基因转录,在骨骼肌、心肌、平滑肌的发育过程中起介导细胞分化的作用。近年来的研究发现,在心力衰竭过程中,MEF2提供了心室重构信号转导过程中的作用靶点,可能参与了心室肥厚与心力衰竭的过程。 Many factors such as long time of workload or excessive nerrohumoral signaling system, can activate a pathological response characterized by hypertrophic growth of cardiaomyocytes, rearrangment of myocyte, increased deposition of extracellular matrix (ECM) proteins and reactivation of fetal cardiac genes. All the above abnormalities will cause pump dysfunction, chamber dilation, myocyte hypertrophy and myocardial fibrosis in the heart and therefore lead to heart failure gradually. MEF2 are specific transcription factors, of which the main function is to control the transcription of genes in muscle differentiation, therefore mediate differentiation during the development of skeletal, cardiac and smooth muscle. Recently, MEF2 are shown to participate in the process of myocyte hypertrophy and heart failure, and may provide a new target for the signal pathways during cardiac remodeling.
出处 《细胞生物学杂志》 CAS CSCD 2008年第5期597-600,共4页 Chinese Journal of Cell Biology
关键词 肌细胞增强因子2 心力衰竭 信号转导 重构 心肌肥厚 MEF2 heart failure signal transduction remodeling hypertropic
  • 相关文献

参考文献29

  • 1Kim Y et al. J Clin Invest, 2008, 118:124
  • 2Frey Net al. Annu Rev Physiol, 2003, 65:45
  • 3McKinsey TA et al. J Clin Invest, 2005, 115:538
  • 4Black BL et al. Annu Rev Cell Dev Biol, 1998, 14:167
  • 5Barsyte-Lovejoy D et al. Biochem J, 2004, 381:693
  • 6Ramachanran Bet al. J Biol Chem, 2008, 283:10318
  • 7Smith JAH et al. Am J Physiol Endocrinol Metab, 2007, 292:E413
  • 8Pan F et al. J Biol Chem, 2004, 279- 14477
  • 9Ma K et al. Mol Cell Biol, 2005, 25:3575
  • 10Ellmers LJ et al. J Mol Endocrinol, 2007, 38:245

二级参考文献9

  • 1Wang L,Fan C,Topol SE,et al.Mutation of MEF2A in an inherited disorder with features of coronary artery disease.Science,2003,302:1578-1581.
  • 2Bhagavatula MR,Fan C,Shen GQ,et al.Transcription factor MEF2A mutations in patients with coronary artery disease.Hum Mol Genet,2004,13:3181-3188.
  • 3Nomenclature and criteria for diagnosis of ischemic heart disease.Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature.Circulation,1979,59:607-609.
  • 4Weng L,Kavaslar N,Ustaszewska A,et al.Lack of MEF2A mutations in coronary artery disease.J Clin Invest,2005,115:1016-1020.
  • 5Yu YT.Distinct domains of myocyte enhancer binding factor-2A determining nuclear localization and cell type-specific transcriptional activity.J Biol Chem,1996,271:24675-24683.
  • 6Wang Q,Rao S,Topol EJ.Miscues on the "lack of MEF2A mutations" in coronary artery disease.J Clin Invest,2005,115:1399-1400.
  • 7Priori SG,Napolitano C,Gasparini M,et al.Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome:A prospective evaluation of 52 families.Circulation,2000,102:2509-2515.
  • 8Black BL,Molkentin JD,Olson EN.Multiple roles for the MyoD basic region in transmission of transcriptional activation signals and interaction with MEF2.Mol Cell Biol,1998,18:69-77.
  • 9McKinsey TA,Zhang CL,Olson EN.MEF2:a calcium-dependent regulator of cell division,differentiation and death.Trends Biochem Sci,2002,27:40-47.

共引文献9

同被引文献20

  • 1Bhagavatula MR, Fan C, Shen GQ, et al. Transcription factor MEF2A mutations in patients with coronary artery disease [ J ]. Hum Mol Genet, 2004,13:3 181 - 3 188.
  • 2Poirier O, Nicaud V, Gariepy J, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocar- dial infarction and carotid intima - media thickness: the ECTIM, AXA, EVA and GENIC studies[J]. Eur J Hum Genet, 2004, 12 : 213-219.
  • 3Sandmann T, Jensen LJ, Jakobsen JS, et al. A temporal map of transcription factor activity: mef2 directly regulates target genesat all stages of muscle development[J]. Dev. Cell, 2006, 10:797 - 807.
  • 4Wang Q, Chen Q. Cardiovascular disease and congenital defects [J]. Nature Encyclopedia of Life Sciences, 2000, 3 : fi46 - fi57.
  • 5Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly[J ]. Annu Rev Physiol, 2003, 65 : 45 - 79.
  • 6Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta- HDL formation and cholesterol efflux to HDL and pro- tects against atherosclerosis[J]. Nat Med, 2005, 11:418 - 422.
  • 7Barsyte - Lovejoy D, Galanis A, Clarity A, et al. ERK5 is targeted to myoeyte enhancer factor 2A (MEF2A) through a MAPK docking motif[J]. Bioehem J, 2004, 381 : 693 - 699.
  • 8Dwyer JH, AUayee H, Dwyer KM, et al. Arachidonate 5 - lipoxy- genase promoter genotype0 dietary arachidonic acid, and atheroselerosis[ J ]. N Engl J Med, 2004, 350:29 - 37.
  • 9Lu J. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class histone deacetylases [ J ]. Mol. Cell, 2000, 6:233 - 244.
  • 10Pezzini A, Grassi M, Del Zotto E, et al. Synergistic effect of apolipoprotein E polymorphisms and cigarette smoking on risk of ischemic stroke in young adults[ J ]. Stroke, 2004, 35 : 438 - 442.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部